214 related articles for article (PubMed ID: 34531667)
1. Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States.
Shah A; Tosh JC; Ambavane A; Nikolaou A; Hogea C; Samyshkin Y; Gorsh B; Maiese EM; Wang F
Clinicoecon Outcomes Res; 2021; 13():789-800. PubMed ID: 34531667
[TBL] [Abstract][Full Text] [Related]
2. Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis.
Nikolaou A; Ambavane A; Shah A; Ma W; Tosh J; Kapetanakis V; Willson J; Wang F; Hogea C; Gorsh B; Gutierrez B; Sapra S; Suvannasankha A; Samyshkin Y
Expert Rev Hematol; 2021 Dec; 14(12):1137-1145. PubMed ID: 34465265
[TBL] [Abstract][Full Text] [Related]
3. US Budget Impact Model for Selinexor in Relapsed or Refractory Multiple Myeloma.
Bassali J; Gould IG; Kaye JA; Mladsi D; Mehta J
Clinicoecon Outcomes Res; 2020; 12():317-325. PubMed ID: 32606848
[TBL] [Abstract][Full Text] [Related]
4. Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model.
Bloudek L; Roy A; Kish JK; Siegel DS; Jagannath S; Globe D; Orloski L; Kuriakose ET
J Manag Care Spec Pharm; 2016 Aug; 22(8):991-1002. PubMed ID: 27459662
[TBL] [Abstract][Full Text] [Related]
5. The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma.
Becnel MR; Lee HC
Ther Adv Hematol; 2020; 11():2040620720979813. PubMed ID: 33403093
[TBL] [Abstract][Full Text] [Related]
6. The Budget Impact of Including Necitumumab on the Formulary for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer: U.S. Commercial Payer and Medicare Perspectives.
Bly CA; Molife C; Brown J; Tawney MK; Carter GC; Cinfio FN; Klein RW
J Manag Care Spec Pharm; 2018 Jun; 24(6):534-543. PubMed ID: 29799326
[TBL] [Abstract][Full Text] [Related]
7. DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma.
Prawitz T; Popat R; Suvannasankha A; Sarri G; Hughes R; Wang F; Hogea C; Ferrante SA; Gorsh B; Willson J; Kapetanakis V
Adv Ther; 2021 Nov; 38(11):5501-5518. PubMed ID: 34561812
[TBL] [Abstract][Full Text] [Related]
8. Budget Impact Analysis of Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US.
Ghanem B; Shi L
Clin Drug Investig; 2022 Dec; 42(12):1085-1092. PubMed ID: 36316586
[TBL] [Abstract][Full Text] [Related]
9. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
[No Abstract] [Full Text] [Related]
10. Budget impact analysis of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer in the United States.
Abraham I; Goyal A; Deniz B; Moran D; Chioda M; MacDonald KM; Huang H
J Manag Care Spec Pharm; 2022 Apr; 28(4):435-448. PubMed ID: 35100006
[No Abstract] [Full Text] [Related]
11. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.
Lonial S; Lee HC; Badros A; Trudel S; Nooka AK; Chari A; Abdallah AO; Callander N; Sborov D; Suvannasankha A; Weisel K; Voorhees PM; Womersley L; Baron J; Piontek T; Lewis E; Opalinska J; Gupta I; Cohen AD
Cancer; 2021 Nov; 127(22):4198-4212. PubMed ID: 34314018
[TBL] [Abstract][Full Text] [Related]
12. US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma.
Dolph M; Tremblay G; Leong H
Clinicoecon Outcomes Res; 2021; 13():493-502. PubMed ID: 34140789
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma.
Suvannasankha A; Bahlis N; Trudel S; Weisel K; Koenecke C; Oriol A; Voorhees PM; Alonso AA; Callander NS; Mateos MV; Reddy N; Hakim S; LaMacchia J; Patel N; Williams D; Jewell RC; Zhou X; Gupta I; Opalinska J; Nooka AK
Cancer; 2024 Apr; ():. PubMed ID: 38630908
[TBL] [Abstract][Full Text] [Related]
14. A budget impact analysis of gilteritinib for the treatment of relapsed or refractory
Pandya BJ; Yang H; Schmeichel C; Qi CZ; Shah MV
J Med Econ; 2021; 24(1):19-28. PubMed ID: 33280474
[TBL] [Abstract][Full Text] [Related]
15. Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma.
Wahab A; Rafae A; Mushtaq K; Masood A; Ehsan H; Khakwani M; Khan A
Front Oncol; 2021; 11():678634. PubMed ID: 34046363
[TBL] [Abstract][Full Text] [Related]
16. Integrated budget impact model to estimate the impact of introducing selpercatinib as a tumor-agnostic treatment option for patients with
Bhandari NR; Gilligan AM; Myers J; Ale-Ali A; Smolen L
J Med Econ; 2024; 27(1):348-358. PubMed ID: 38334069
[TBL] [Abstract][Full Text] [Related]
17. Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA.
Lin SW; Shapouri S; Parisé H; Bercaw E; Wu M; Kim E; Matasar M
Pharmacoeconomics; 2024 May; 42(5):569-582. PubMed ID: 38300452
[TBL] [Abstract][Full Text] [Related]
18. Budget impact of tepotinib in the treatment of adult patients with metastatic non-small cell lung cancer harboring
Stargardter M; McBride A; Tosh J; Sachdev R; Yang M; Ambavane A; Mittal M; Vioix H; Liu FX
J Med Econ; 2021; 24(1):816-827. PubMed ID: 34126842
[TBL] [Abstract][Full Text] [Related]
19. Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma.
Neupane K; Wahab A; Masood A; Faraz T; Bahram S; Ehsan H; Hannan A; Anwer F
J Blood Med; 2021; 12():529-550. PubMed ID: 34234609
[TBL] [Abstract][Full Text] [Related]
20. Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.
Nooka AK; Cohen AD; Lee HC; Badros A; Suvannasankha A; Callander N; Abdallah AO; Trudel S; Chari A; Libby EN; Chaudhry M; Hultcrantz M; Kortüm KM; Popat R; Sborov D; Hakim S; Lewis E; Gorsh B; Bhushan B; McKeown A; Gupta I; Opalinska J; Richardson PG; Lonial S
Cancer; 2023 Dec; 129(23):3746-3760. PubMed ID: 37622738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
